Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Yongjie Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-3595-0866; OpenAlex author ID A5032050651, A5101015393. Sources: OpenAlex.

Their work

Papers
30 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 6 papers · 2024: 6 papers · 2025: 8 papers · 2026: 6 papers

Papers 30

  1. Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Co-author DOI 10.1002/advs.202507346↗
  2. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4↗
  3. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  4. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  5. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Co-author DOI 10.1136/gutjnl-2025-336277↗
  6. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  7. Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Co-author DOI 10.1002/advs.202509930↗
  8. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  9. The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2025.111098↗
  10. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  11. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  12. Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-025-68099-0↗
  13. Hypoxic and Acidic Tumor Microenvironment-Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. First author DOI 10.1053/j.gastro.2024.10.042↗
  14. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  15. Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. First author DOI 10.1016/j.isci.2024.109045↗
  16. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. First author DOI 10.1016/j.surg.2024.07.047↗
  17. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  18. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  19. Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportu… Co-author DOI 10.1186/s12575-024-00254-1↗
  20. PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3952664/v1↗
  21. ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer. First author DOI 10.1007/s12672-023-00690-7↗
  22. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  23. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  24. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. First author DOI 10.1186/s13046-023-02671-8↗
  25. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Co-author DOI 10.1186/s13046-023-02814-x↗
  26. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2022.0569↗
  27. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  28. Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC. Co-author DOI 10.3389/fcell.2022.762372↗
  29. DDX31: A Novel Functional Oncogene Promotes Migration and Proliferation of Pancreatic Cancer First author DOI 10.21203/rs.3.rs-520114/v1↗
  30. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.698302↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 20 shared papers, 2022–2026 · strength 3.73
  2. Tianxing Zhou · 17 shared papers, 2022–2026 · strength 3.15
  3. Xiuchao Wang · 15 shared papers, 2022–2026 · strength 2.74
  4. Tiansuo Zhao · 13 shared papers, 2022–2026 · strength 2.33
  5. Chongbiao Huang · 11 shared papers, 2022–2026 · strength 1.87
  6. Bo Ni · 7 shared papers, 2022–2025 · strength 1.38
  7. Shengyu Yang · 8 shared papers, 2022–2026 · strength 1.35
  8. Jing Liu · 8 shared papers, 2022–2026 · strength 1.33
  9. Yukuan Feng · 6 shared papers, 2025–2026 · strength 1.23
  10. Jun Yu · 6 shared papers, 2024–2026 · strength 1.15
  11. Song Gao · 7 shared papers, 2022–2026 · strength 1.15
  12. Chao Yang · 5 shared papers, 2025–2026 · strength 0.99
  13. Yiping Zou · 5 shared papers, 2023–2025 · strength 0.88
  14. Qingxiao Fang · 4 shared papers, 2025–2026 · strength 0.79
  15. Weishuai Liu · 4 shared papers, 2023–2025 · strength 0.78
  16. Jinsheng Ding · 4 shared papers, 2021–2025 · strength 0.75
  17. Liangliang Wu · 4 shared papers, 2021–2025 · strength 0.74
  18. Wenna Jiang · 5 shared papers, 2022–2024 · strength 0.71
  19. Chuntao Gao · 4 shared papers, 2021–2026 · strength 0.70
  20. Yifei Wang · 3 shared papers, 2026 · strength 0.67
  21. Shangheng Shi · 3 shared papers, 2026 · strength 0.62
  22. Chao Xu · 3 shared papers, 2023–2026 · strength 0.57
  23. Yang Liu · 3 shared papers, 2021–2022 · strength 0.48
  24. Xiaofan Guo · 2 shared papers, 2026 · strength 0.46
  25. Weihao Zhang · 2 shared papers, 2023–2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.